Titan Pharmaceuticals Inc
TTNPDelisted Oct 2, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000910267
Titan Pharmaceuticals Inc was delisted on Oct 2, 2025; its insiders filed their last Form 4 on Oct 8, 2025; 18 institutions reported holding it in 13F filings for Q3 2025, worth $107.1K in total; no superinvestor held it.
Q1 2024 vs. Q4 2023
How the institutions holding Titan Pharmaceuticals Inc changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 24 | 17 | −7 |
| Shares | 1.01M | 32.1K | −974.6K (−96.8%) |
| Value | $408.2K | $230.0K | −$178.2K (−43.7%) |
New holders (4)
Institutions that held Titan Pharmaceuticals Inc at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| MCF Advisors LLC | 165 | $1.18K | 0.00% |
| Nemes Rush Group LLC | 1 | $8 | 0.00% |
| Cape Investment Advisory, Inc. | 1 | $7 | 0.00% |
| Ransom Advisory, Ltd | 1 | $7 | 0.00% |
Sold out (11)
Institutions that held Titan Pharmaceuticals Inc at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Renaissance Technologies LLC | 135,310 | $56.0K |
| Vanguard Group Inc | 82,051 | $33.8K |
| Geode Capital Management, LLC | 87,945 | $29.0K |
| State Street Corp | 38,287 | $15.8K |
| Susquehanna International Group, LLP | 19,596 | $8.08K |
| Millennium Management LLC | 15,113 | $6.23K |
| Level Financial Advisors, Inc. | 987 | $407 |
| JPMorgan Chase & Co | 154 | $64 |
| BlackRock Inc. | 60 | $25 |
| Qube Research & Technologies Ltd | 4 | $2 |
| Newbridge Financial Services Group, Inc. | 2 | $1 |